BEIJING (Reuters) – Coronavirus vaccines being developed in China could be ready for public use as early as November, an official at the Chinese Center for Disease Control and Prevention (CDC) said.
China has four COVID-19 vaccines in the final phase of clinical trials. At least three of these have already been offered to essential workers as part of an emergency use program launched in July.
Phase 3 clinical trials were progressing smoothly and vaccines could be ready for the general public in November or December, Guizhen Wu, the CDC’s chief biosecurity expert, said Monday in an interview with state TV.
Wu, who said she hadn̵
A unit of the state-owned pharmaceutical giant China National Pharmaceutical Group (Sinopharm) and Sinovac Biotech listed in the United States
Sinopharm said in July that its vaccine could be ready for public use by the end of this year, following the conclusion of phase 3 studies.
Global vaccine manufacturers are racing to develop an effective vaccine against the virus that has killed more than 925,000 people. Leading Western vaccine manufacturers pledged earlier this month to uphold the standards of scientific studies and reject any political pressure to speed up the process.
(This story corrects typos in lede; the Chinese CDC uses the American-style center in the title)
(Reporting by Roxanne Liu and Tony Munroe in Beijing; Editing by Miyoung Kim and Jane Wardell)